Report Library
View More
2025 Deal-making Roundup
April 20, 2026
Hidradenitis Suppurativa KOL Interv...
April 20, 2026
Hidradenitis Suppurativa KOL Interv...
April 20, 2026
Hidradenitis Suppurativa KOL Interv...
April 16, 2026
Idiopathic Pulmonary Fibrosis KOL I...
April 15, 2026
Idiopathic Pulmonary Fibrosis KOL I...
April 14, 2026
Idiopathic Pulmonary Fibrosis KOL I...
April 13, 2026
Hidradenitis Suppurativa KOL Interv...
April 10, 2026
Datamonitor Healthcare CNS Disease ...
April 7, 2026
Acute Lymphoblastic Leukemia KOL In...
April 1, 2026
Acute Lymphoblastic Leukemia KOL In...
March 31, 2026
Acute Lymphoblastic Leukemia KOL In...
March 31, 2026
Acute Lymphoblastic Leukemia KOL In...
March 30, 2026
Acute Lymphoblastic Leukemia KOL In...
March 30, 2026
Datamonitor Healthcare I&I Disease ...
March 30, 2026
Datamonitor Healthcare CV&Met: Veno...
March 10, 2026
Datamonitor Healthcare CV&Met: Atri...
March 10, 2026
Datamonitor Healthcare Oncology: Sm...
March 10, 2026
Datamonitor Healthcare I&I: Glaucom...
March 10, 2026
Bio Asia 2026 Conference Dispatch
March 9, 2026
Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 4/22/26 | Anthos Therapeutics | abelacimab for Venous Thromboembolism (VTE) | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/13/26 | Eli Lilly and Company (LLY) | Jaypirca for Non-Hodgkin's Lymphoma (NHL) | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/13/26 | Eli Lilly and Company (LLY) | Jaypirca for Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/13/26 | SynOx Therapeutics | emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) / Pigmented Villonodular Synovitis (PVNS) | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/13/26 | Revolution Medicines (RVMD) | daraxonrasib for Pancreatic Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 10/22/2023 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 10/22/2023 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |